Update on the treatment of disseminated fusariosis: Focus on voriconazole
Authors Marta Stanzani, Fabio Tumietto, Nicola Vianelli, Michele Baccarani
Published 15 January 2008 Volume 2007:3(6) Pages 1165—1173
Marta Stanzani1, Fabio Tumietto2, Nicola Vianelli1, Michele Baccarani1
1Institute of Haematology and Clinical Oncology “Ariosto e Lorenzo Seràgnoli”, S. Orsola-Malpighi Hospital, University of Bologna, Italy; 2Division of Infectious Diseases, S. Orsola-Malpighi Hospital, University of Bologna, Italy
Abstract: Invasive fungal infections are a major cause of morbidity and mortality in immunocompromised patients, such as subjects with hematological malignancies and patients who underwent to hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT). Fusarium spp. cause a broad spectrum of infections in humans. Immunologically competent hosts show mainly localized skin infections, whereas disseminated fusariosis occurs almost exclusively in immunocompromised patients. Fusarium spp. are resistant to many antifungal agents with equivocal in vitro and in vivo susceptibility to amphotericin B. Voriconazole (VRC) is a triazole shown to be safe, well tolerated, and in vitro efficacious against Fusarium spp. Although clinical experience is limited, many case reports have shown the efficacy of VRC in the treatment of fusariosis.
Keywords: fusariosis, voriconazole, immunocompromised patient, cancer, fungal infections, aspergillus